Body Mass Index and Obesity Surgery Mortality Risk Score in Perioperative Complications of Laparoscopic Sleeve Gastrectomy

June 13, 2020 updated by: Mehmet Buğra Bozan, Kahramanmaras Sutcu Imam University

Is Body Mass Index and Obesity Surgery Mortality Risk Score Important in Perioperative Complications of Laparoscopic Sleeve Gastrectomy Before Discharge? A Retrospective Cohort Study

The term obesity is defined as body mass index (BMI) 30 and over, and morbid obesity is considered as BMI greater than 40 (1).Its incidence in the general population is approximately 20% according to Organisation for data of Economic Co-operation and Development (OECD) countries and unfortunately, it is increasing worldwide (2). Obesity should not be thought ofas a single disorderasit is related tomany disorders like hypertension, diabetes, obstructive sleep apnea, cardiovascular diseases, and increased risk of malignancies (1).For years people have struggled with obesitywithboth metabolic and physical problems. Surgical treatment is the most effective long-term therapeutic treatment in current and modern medicine of obesity and obesity-related diseases as the last resort.(3-5). Roux-en-y gastrojejunostomy is the method that has been applied for many years and there isconsensus on its effect.However, in recent years, laparoscopic sleeve gastrectomy (LSG) has an increasing number of procedures with a short learning curve and it is the most performed surgical technique all over the world and also in Turkey (2,6).

Unfortunately, like any surgical procedure, this surgery has its own complications.Although being performed frequently increases the experience of surgeons, this situation cannot reduce the risk of complications of surgery to zero. In morbid obesity patients, the risk of any complications in all surgical procedures is higher than withother patients who were not morbidly obese. Due to these complications, prolonged hospital stays, increased reapplications to the hospital, reoperations and deaths can result(5,7). Despite both an increased risk of complications according to obesity and the risk of specific complications due to sleeve gastrectomy, laparoscopic sleeve gastrectomy is associated with acceptable postoperative morbidity and mortality rates (8).

Various classifications have been described in the literature for complications after surgery.In one of these classifications, according to Clavien-Dindo (CD) Classification, complications are divided into two groups as major and minor. (1, 9)(Table 1). This classification can be applied to bariatric and metabolic surgeries as withall surgery types. Especially major complications in this classification are life-threatening situations and their early detection is important (8).

In fact, surgeons do not want to encounter mortality in any of their patients. In this respect, DeMaria et al. developed an easily applicable mortality risk scoring system, which is consisted of five items (age ≥45 years, male sex, body mass index (BMI) ≥ 50 kg / m2, arterial hypertension, and risk factors for pulmonary thromboembolism) and can be used for the pre-operative determination of risky patients in obesity surgery(Obesity Surgery Mortality Risk Score; OR-MRS) (8,10,11).

In this study, it is aimed to determine the perioperative complications seen in the laparoscopic sleeve gastrectomy patients that we performed in our clinic without being discharged from the hospital and to evaluate the treatment processes of the complications under literature. In addition, whether the OS-MRS risk assessment scale and BMI had a role indetermining perioperative complications before discharge was investigated.

Study Overview

Detailed Description

Material - Method Our study was carried out with the approval numbered 13281952-929 from Elazig Training and Research Hospital. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 1752 patients who met the criteria of patient selection in terms of obesity and metabolic disease surgery, operated in the Elazığ Training and Research Hospital General Surgery Clinic between January 2016 and October 2018 were evaluated retrospectively. Patients' data were obtained from epicrisis forms in the hospital computer system, patient follow-up charts and patient files. Data for OS-MRS and Clavien Dindo complication classification were obtained from patient follow-up charts, patient files and hospital computer records. Patients' demographic data (age, sex), presence of comorbidities, complications (wound complications, thromboembolic events, leakage from anastomosis, splenic infarction proven by imaging methods, bleeding detected due to low hemoglobin and hematocite values during follow-up, acute renal failure due to deterioration in biochemical parameters) seen in follow up period before discharge (postoperative first 72 hours), complication type (major and minor), whether emergency surgery was performed, BMI values, postoperative hospitalization and OS-MRS. Additionally, while grouping according to BMI values, patients with BMI values below 40 were excluded and three groups with BMI values of 40 - 45 kg / m^2, 45 - 50 kg / m^2 and 50 kg / m^2 and above were created. It was investigated whether there were any complications among these groups and the presence of major or minor complications by CD classification. 1617 patients who met the inclusion criteria were evaluated.

IBM Statistical Package for Social Sciences (SPSS) 20.0 was used for statistical evaluation. Kolmogorow-Smirnov test results were examined in terms of the suitability of the groups for normal distribution. In comparisons between groups, independent sample t-test or Mann Whitney U test was used to evaluate numerical data according to normality test. In the evaluation of categorical data, chi-square analysis and Fischer's exact test were performed. In terms of the relation between complication formation and BMI, univariate analysis and multivariate analysis were performed. Numerical data were given as mean ± standard deviation (ss) (minimum - maximum values) or median (minimum - maximum values) according to normality test. Categorical data are given as count (n) and percentage (%).

Study Type

Observational

Enrollment (Actual)

1617

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patient selection in terms of obesity and metabolic disease surgery(12);

  1. Patients with a body mass index (BMI) of 40 and above, without the additional comorbid disease,
  2. Patients with a BMI of 35 and above, withtheadditional comorbid disease (such as hypertension, diabetes mellitus)

Description

Inclusion Criteria:

  • Patients whose data was available
  • Morbid obesity patients who were operated with surgical technique laparoscopic sleeve gastrectomy

Exclusion Criteria:

  • Patients whose data was not available
  • Patients who were operated with other types of bariatric metabolic surgery
  • Patients who left the hospital due to referral
  • Patients whose OS-MRS scale wasn't calculated
  • Patients whose American Society of Anesthesiologists (ASA) score was 4 or greater

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Complication positive
Patients with perioeprative complications after laparascopic sleeve gastrectomy before discharge (wound complications, thromboembolic events, staple line leakage, splenic infarction proven by imaging modalities, bleeding detected due to low hemoglobin and hematocrit values during follow-up, acute renal failure due to deterioration in biochemical parameters)
Operations performed for complciation of laparascopic sleeve gastrectomy
Other Names:
  • Reoperation
İnterventional radiologic drainage of gastric leakage
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Admitted to observe leakage
Complication negative
Patients without perioeprative complications after laparascopic sleeve gastrectomy before discharge
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
BMI 40 - 45 kg/m2
Operated patients preoperative BMI values between 40 - 45 kg/m2
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
BMI 45 - 50 kg/m2
Operated patients preoperative BMI values between 45 - 50 kg/m2
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
BMI over 50 kg/m2
Operated patients preoperative BMI values 45 - 50 kg/m2
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Clavien Dindo Major Complications
  1. Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Acceptable therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy This grade also includes wound infections opened at the bedside
  2. Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions, antibiotics and total parenteral nutrition are also included
Operations performed for complciation of laparascopic sleeve gastrectomy
Other Names:
  • Reoperation
İnterventional radiologic drainage of gastric leakage
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Admitted to observe leakage
Clavien Dindo Minor Complciations
3. Requiring surgical, endoscopic or radiological intervention 3a Intervention under regional/local anaesthesia 3b Intervention under general anaesthesia 4. Life-threatening complication requiring intensive care/intensive care unit management 4a Single-organ dysfunction 4b Multi-organ dysfunction 5. Patient demise
İnterventional radiologic drainage of gastric leakage
blood samples obtained from patients to determine the hgb and htc levels of patients and biochemical changes of patients after surgery
Admitted to observe leakage

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relation between preoperative BMI levels and perioperative complication positivity before discharge
Time Frame: postoperative 72 hour period before discharge
Relation between preoperative BMI levels and perioperative complication positivity before discharge
postoperative 72 hour period before discharge
Relation between preoperative OS-MRS and perioperative complication positivity before discharge
Time Frame: postoperative 72 hour period before discharge
Relation between preoperative OS-MRS and perioperative complication positivity before discharge
postoperative 72 hour period before discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perioperative complication rates after laparascopic sleeve gastrectomy before discharge
Time Frame: postoperative 72 hour period before discharge
Perioperative complication rates after laparascopic sleeve gastrectomy before discharge
postoperative 72 hour period before discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2016

Primary Completion (Actual)

October 1, 2018

Study Completion (Actual)

January 1, 2019

Study Registration Dates

First Submitted

June 6, 2020

First Submitted That Met QC Criteria

June 9, 2020

First Posted (Actual)

June 11, 2020

Study Record Updates

Last Update Posted (Actual)

June 16, 2020

Last Update Submitted That Met QC Criteria

June 13, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Morbid

Clinical Trials on Laparascopic Sleeve Gastrectomy

Subscribe